Marketing information about cartegravir injection

Cabotegravir injection (Cabotegravir), as an innovative HIV pre-exposure prophylaxis drug, has recently attracted widespread attention in the medical community. The drug is the first long-acting injectable preparation approved by the U.S. Food and Drug Administration (FDA) and is designed for adults and adolescents weighing at least 35kg to reduce their risk of contracting HIV-1 through sexual intercourse.

Categravir injection has a unique mechanism of action. It is an integrase inhibitor that can block the integrase enzyme activity necessary for the HIV-1 virus to replicate itself in the body. Clinical trial data shows that when used correctly, the drug is as effective as 99% effective in preventing HIV-1 viral transmission, providing a new option for those seeking efficient prevention methods. Before starting treatment, patients need to test negative for HIV to ensure drug resistance does not develop.

The long-acting injectable form of cartegravir injection significantly improves patient compliance compared with daily oral formulations. Particularly in the United States, while more people are taking PrEP (pre-exposure prophylaxis) to prevent HIV, adhering to daily medication remains a challenge for certain high-risk individuals and groups. The availability of long-acting injectable PrEP options is expected to increase PrEP uptake and compliance among these groups, leading to better control of HIV transmission.

On December 20, 2021, cartegravir injection was successfully launched in the United States under the trade name APRETUDE. Subsequently, in 2023, the drug was also approved by the my country Food and Drug Administration and was launched in China under the trade name Wankairui. Although cartegravir injection has not yet been included in medical insurance, and the price of its original European version is relatively high, about RMB 16,000, its unique advantages and efficacy make it a bright new star in the field of HIV prevention.

Reference link:https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212887s007lbl.pdf